Advertisement

Topics

Latest "Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis" News Stories

08:44 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis" found in our extensive news archives from over 250 global news sources.

More Information about Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis for you to read. Along with our medical data and news we also list Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis Clinical Trials, which are updated daily. BioPortfolio also has a large database of Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis Companies for you to search.

Showing "Adamis Pharmaceuticals Corp ADMP Financial Strategic SWOT Analysis" News Articles 1–25 of 31,000+

Tuesday 25th September 2018

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

– ALTA-1L Met its Primary Endpoint Showing Superiority in Blinded Independent Review Committee-Assessed Progression-Free Survival Compared to Crizotinib – – Data Will Be Presented During the Presidential Symposium at the 19th World Conference on Lung Cancer (WCLC) with Simultaneous Publication in The New England Journal of Medicine – ...


China ENT Devices Market Outlook to 2025 [Report Updated: 01052018] Prices from USD $5995

China ENT Devices Market Outlook to 2025SummaryGlobalData's new report, China ENT Devices Market Outlook to 2025, provides key market data on the China ENT Devices market. The report provides value, in millions of US dollars, volume in units and average prices USD within market categories Diagnostic Devices, Hearing Aid Devices, Hearing Implants, Nasal Splints and Speech Aid Devices.The report al...

IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer

IMFINZI reduced the risk of death by nearly one-third compared to placebo in the Phase III PACIFIC trial Updated data reaffirm unprecedented improvement in progression-free survival of more than 11 months AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III ...


Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team

Pharmaceutical outsourcing marketplace adds Chief Business Officer to oversee company’s rapid worldwide expansion Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced today the appointment of Mark Herbert to its senior leadership team. As the company’s chief business officer, he will focus on co...

$TGTX DSMB says interim analysis of ORR could not be conducted at this time as the data were not sufficiently mature to conduct the analysis.

$TGTX DSMB says interim analysis of ORR could not be conducted at this time as the data were not sufficiently mature to conduct the analysis.

Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association

-- Horizon to host an investor call on Oct. 4 following the teprotumumab data presentation -- Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of moderate-to-severe active thyroid eye disease (TED). The data will be presented on Oct. 4, 2018, at the...

Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy

-- Pivotal Study of Novel Inhibitor of NF-kB, a Key Driver of Skeletal Muscle Disease and Cardiomyopathy in Duchenne -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of Po

Millendo Therapeutics Appoints Habib Dable to Its Board of Directors

Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the Company’s Board of Directors. “Habib brings to our board an exceptional mix of executive and ...

VenatoRx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

VenatoRx is eligible to receive up to $114 million, including upfront and milestone payments, in addition to royalties VenatoRx Pharmaceuticals, Inc., a world leader in antibacterial and antiviral drug research and development, today announced that it entered into an exclusive license agreement (“License Agreement”) with Evere

Roche’s Tecentriq plus chemotherapy reduces death risk in lung cancer study

The interim analysis of the phase III IMpower132 study has demonstrated that Tecentriq and chemotherapy reduced the risk of disease worsening or death (progression-free survival (PFS)) by 40% The post Roche’s Tecentriq plus chemotherapy reduces death risk in lung cancer study appeared first on Pharma Business review.

Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer

Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung cancer and other...

Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: The 14th Annual Meeting of the Oligonucleotide Therapeutics Society – Seattle, September 30-October 3, 2018 October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-...

LabVantage Solutions Names John Heiser Chief Executive Officer

—New CEO Brings Deep and Diverse Skill Set and Record of Strong Leadership in Building Global Technology and Life Sciences Businesses— —LabVantage Is a Leading Global Provider of Laboratory Informatics Services Offering Purpose-Built Solutions that Bundle Its LIMS Software with Features Tailored to Industry-Specific Needs— LabVa...

Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. “Dr. Brennan has an impressive track record of success in advancing the development of numerous drug candidates throughout her career, with experience in the fields of rare disease, hematology, and neurology, among oth...

KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 8:00 a.m. ET in New York, NY. A live webcast of th...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Cantor ...

UK launch for Ferring’s new testosterone replacement therapy

Ferring Pharmaceuticals has launched testosterone replacement therapy Testavan in the UK.

Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY, on Wednesday, October 3 at 3:2...

RTI Surgical® Wins 2018 Orthopedics This Week Spine Technology Award for TETRAfuse® 3D Technology

Award recognizes excellence and innovation in spine surgery products RTI Surgical, Inc. (Nasdaq:RTIX), a global surgical implant company, announced its TETRAfuse® 3D Technology won a 2018 Spine Technology Award from Orthopedics This Week, a widely read publication in the orthopedics industry. RTI will accept the award at the North American Spine Socie...

Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00 PM ET at the InterContine...

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

- Gaurav Shah, M.D., Chief Executive Officer, Invited as Panel Member at The Galien Forum USA 2018 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that members of Rocket’s executive team will participate in the following upcoming conferences: ...

Cerveau Technologies Signs Research Agreement with Ionis Pharmaceuticals

NewsThe collaboration is focused on using [F-18]MK-6240 as a biomarker in Ionis neurodegenerative disease research studies.Con

NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care

Studies Show Significantly Reduced Complications, Improved Service Capacity, and Decreased Costs NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K...

Medios AG publishes half-year financial report 2018 - growth path continues

DGAP-News: Medios AG / Key word(s): Half Year Results 25.09.2018 / 10:27 The issuer is solely responsible for the content of this announcement. Medios AG publishes half-year financial report 2018 - growth path continues Strong demand for individualised medicine Expansion of number of partner pharmacies Revenues increase by 24% to EUR 145 million EBT* grows by 22% to EUR 4.7 millio...

Canada Hip Reconstruction Market Outlook to 2025 [Report Updated: 04062018] Prices from USD $4995

Canada Hip Reconstruction Market Outlook to 2025SummaryGlobalData's new report, Canada Hip Reconstruction Market Outlook to 2025, provides key market data on the Canada Hip Reconstruction market. The report provides value, in millions of US dollars, volume in units and average prices USD within market categories Hip Resurfacing, Partial Hip Replacement, Primary Hip Replacement and Revision Hip Re...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks